TW201532603A - 肝癌之預防及／或治療劑 - Google Patents

肝癌之預防及／或治療劑 Download PDF

Info

Publication number
TW201532603A
TW201532603A TW103113223A TW103113223A TW201532603A TW 201532603 A TW201532603 A TW 201532603A TW 103113223 A TW103113223 A TW 103113223A TW 103113223 A TW103113223 A TW 103113223A TW 201532603 A TW201532603 A TW 201532603A
Authority
TW
Taiwan
Prior art keywords
salt
liver cancer
medicine
treatment
solvent
Prior art date
Application number
TW103113223A
Other languages
English (en)
Chinese (zh)
Inventor
Hitoshi Yoshiji
Hiroshi Fukui
Original Assignee
Public University Corp Nara Medical University
Kowa Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Public University Corp Nara Medical University, Kowa Co filed Critical Public University Corp Nara Medical University
Publication of TW201532603A publication Critical patent/TW201532603A/zh

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A61K31/202—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids having three or more double bonds, e.g. linolenic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Engineering & Computer Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Molecular Biology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
TW103113223A 2013-04-10 2014-04-10 肝癌之預防及／或治療劑 TW201532603A (zh)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP2013081708 2013-04-10

Publications (1)

Publication Number Publication Date
TW201532603A true TW201532603A (zh) 2015-09-01

Family

ID=51689596

Family Applications (1)

Application Number Title Priority Date Filing Date
TW103113223A TW201532603A (zh) 2013-04-10 2014-04-10 肝癌之預防及／或治療劑

Country Status (3)

Country Link
JP (1) JP6702722B2 (ja)
TW (1) TW201532603A (ja)
WO (1) WO2014168191A1 (ja)

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2597247A1 (en) * 2005-02-11 2006-08-17 Regeneron Pharmaceuticals, Inc. Therapeutic combination of a vegf antagonist (vegf trap) and an anti-hypertensive agent
EP1937288A4 (en) * 2005-10-11 2012-04-04 Lycored Ltd OXIDATION PRODUCTS OF CAROTENOIDS AS CHEMOPREVENTIVE AND CHEMOTHERAPEUTIC AGENTS
TWI501763B (zh) * 2010-08-11 2015-10-01 Kowa Co Hepatocellular carcinoma is treated with a relapse after treatment
WO2012068531A2 (en) * 2010-11-18 2012-05-24 The General Hospital Corporation Novel compositions and uses of anti-hypertension agents for cancer therapy

Also Published As

Publication number Publication date
WO2014168191A1 (ja) 2014-10-16
JPWO2014168191A1 (ja) 2017-02-16
JP6702722B2 (ja) 2020-06-03

Similar Documents

Publication Publication Date Title
JP6401317B2 (ja) がんを治療するためのシステム、方法、および製剤
JP6516341B2 (ja) Ｎａｓｈ関連肝臓癌を治療するためのｅｐ４受容体拮抗薬の使用
Whang-Peng et al. Clinical development and future direction for the treatment of hepatocellular carcinoma
WO2014142220A1 (ja) 抗腫瘍剤
JP2014533701A5 (ja)
JP5636108B2 (ja) 癌を治療するための、レチノール、その前駆体または反応性生物および少なくとも１つのカモミール植物からの植物抽出液を含む組成物
JP6359583B2 (ja) 肝細胞がんの予防及び／又は治療のための医薬
WO2012075754A1 (zh) 一种治疗急性淋巴白血病的复方药物组合物
JP2014237642A (ja) 癌治療用組成物の調製のためのイカリチンの使用
CA3134156A1 (en) Chiauranib for treatment of small cell lung cancer
CN104968340A (zh) 治疗肝脏疾病或病状的用途和方法
WO2014047782A1 (zh) 含有白藜芦醇及白藜芦醇类衍生物和Bcl-2抑制剂的药物组合物及其应用
TW201532603A (zh) 肝癌之預防及／或治療劑
WO2014172857A1 (zh) 阿可拉定在制备用于治疗原发性肝癌的药物中的用途
CN110831597A (zh) 肝细胞癌的治疗
CN105663028B (zh) 一种含去水卫矛醇的经直肠给药双层缓释栓剂
KR102412352B1 (ko) ERR-α 억제제를 유효성분으로 하는 백혈병 치료용 약학 조성물
WO2014047779A1 (zh) 含有吴茱萸碱及吴茱萸碱类衍生物和Bcl-2抑制剂的药物组合物及其应用
CN117357534A (zh) 包含维甲酸的药物组合物在制备治疗肝细胞癌伴腹腔转移的药物中的用途
EP3593798A1 (en) Medical uses of n-(2-aminoethyl)-n-(4-benzyloxy)-3-methoxybenzyl)thiophene-2-formamide hydrochloride
OA19197A (en) Pharmaceutical composition for use in the theurapeutic treatment of cancer and complications of cancer.
Kapila et al. Hepatic Epithelioid Hemangioendothelioma Complicated by Esophageal Variceal Bleeding: 849
Nguyen et al. Ledipasvir/Sofosbuvir in the Treatment of Hepatitis C Virus Genotype 6: 850
Nair et al. An Elusive Source of Chronic Gastrointestinal Bleeding After a Whipple Procedure: 851
CN105326823A (zh) 一种用于抑制肝细胞癌的药物